Drug intelligence / Profile preview

CAR-503

Development stage: Preclinical
Lead developer: Carmel Biosciences
Modality: Small Molecules

Overview

CAR-503 is an early-stage drug candidate currently under development by Carmel Biosciences. It is positioned within the company's pipeline for cardiovascular and metabolic diseases. As of the latest reports, the program is in the pre-Investigational New Drug (pre-IND) phase, indicating it is in early preclinical development. Carmel Biosciences typically focuses on the re-engineering of established therapeutic agents to create novel formulations with improved clinical profiles, such as enhanced bioavailability or reduced side effects. However, specific details regarding the active pharmaceutical ingredient, molecular target, and precise mechanism of action for CAR-503 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on CAR-503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-503.

Explore the full profile